## Salmefamol: inhibitor or stimulant of gastric acid secretion?

S.P. CANFIELD, B.P. CURWAIN, J.A. KING & CAROLYN PRICE

Department of Physiology, St Mary's Hospital Medical School, London W2 1PG

 $\beta_2$ -Adrenoceptor agonists have been shown to inhibit pentagastrin-induced gastric acid secretion in both dog (Curwain, Holton & Spencer, 1972; Daly & Stables, 1977) and rat (Lundell & Svensson, 1974). We have investigated the action of a drug of this type, salmefamol, on gastric acid secretion and mucosal blood flow (MBF) in 4 conscious dogs with well-established Heidenhain pouches and also in a rat isolated stomach preparation. The results showed the expected inhibition of secretion in the dog but there was a stimulation of acid output by salmefamol in the *in vitro* preparation.

Submaximal doses of either pentagastrin (2µg kg<sup>-1</sup> h<sup>-1</sup>) or bethanechol chloride (1μg kg<sup>-1</sup> min<sup>-1</sup>) were infused i.v. in saline (1 ml/min) in the dogs until a plateau of acid secretion was obtained. MBF was estimated by radioactive aniline clearance (Curwain & Holton, 1973). Salmefamol (0.2 or 0.8 μg kg<sup>-1</sup> min<sup>-1</sup> i.v. for 30 min) was tested against each secretagogue in each of the 4 dogs. The control rates of acid secretion and MBF were taken as the mean values for the 4 successive 15 min periods immediately before giving salmefamol. The means of the 2 successive 15 min samples giving the lowest rate of acid secretion were used as test values. Secretory rate was profoundly decreased (between 33 and 98%, mean 76%) in each of the 8 experiments. Changes in MBF were variable but in each experiment the ratio of blood flow to secretion increased.

The isolated stomachs from rats (35–50 g) were set up as described for the guinea pig by Holton & Spencer (1976) and were stimulated with either bethanechol chloride ( $1.7 \times 10^{-5}$ M) or pentagastrin ( $2 \times 10^{-5}$ M). The acid output was measured over four 15

min periods. The drug was then washed out and the tissues incubated for 1 h with salmefamol (10<sup>-5</sup>M) before a second dose of the same stimulant was added in the presence of salmefamol. The results are expressed as the percentage increase above the spontaneous secretory rate in the absence of drugs.

The mean increase in acid output due to the pentagastrin alone was  $185 \pm 4.7\%$  and  $299 \pm 15.6\%$  in the presence of pentagastrin and salmefamol (s.e., n = 3). The values for bethanechol were  $276 \pm 88\%$  and  $356 \pm 72\%$  (n = 3) respectively. The results do not show any evidence of inhibition of the secretory response. Paired t tests indicated that the increase in the response in the presence of salmefamol was significant both for bethanechol (P < 0.05) and pentagastrin (P < 0.02). Salmefamol alone ( $10^{-5}$ M) increased the rate of acid secretion by  $231 \pm 19\%$  (n = 6).

The concentration dependence of this salmefamolstimulated acid secretion and the action upon it of various established inhibitors of acid output is being investigated.

## References

CURWAIN, B.P. & HOLTON, P. (1973). The measurement of dog gastric mucosal blood flow by radioactive aniline clearance compared with amidopyrine clearance. *J. Physiol. Lond.*, 229, 115–131.

CURWAIN, B.P., HOLTON, P. & SPENCER, J. (1972). The effect of β<sub>2</sub>-adrenoceptor stimulants, salbutamol and terbutaline on gastric acid secretion and mucosal blood flow in conscious dogs with Heidenhain pouches. *Br. J. Pharmac.*, 46, 566–567P.

DALY, M.J. & STABLES, R. (1977). The effect of (-)-isoprenaline and (±)-salbutamol on pepsinogen and acid secretion in the dog. *Br. J. Pharmac.*, **59**, 323-325.

HOLTON, P. & SPENCER, J. (1976). Acid secretion by guinea-pig isolated stomach. J. Physiol., Lond., 255, 465-479P.

LUNDELL, L. & SVENSSON, S.E. (1974). Implication of gastric mucosal histamine in inhibition by isoprenaline of pentagastrin-induced gastric secretion. *Br. J. Pharmac*. 52, 69-75.

## Comparative assay of histamine H<sub>2</sub>-receptor antagonists using the isolated mouse stomach

J.A. ANGUS\*, J.W. BLACK & M. STONE

Departments of Pharmacology, and Statistics & Computer Science, University College London

There is still insufficient evidence about the nature of the interaction between H<sub>2</sub>-receptor antagonists and histamine on gastric acid secretion to argue that the inhibition of physiologically-induced acid secretion is due to blockade of histamine receptors. Bunce & Parsons (1976), using isolated rat stomachs, found a pA<sub>2</sub> value for metiamide equivalent to that measured in atrial and uterine tissues but the slope of the Schild plot of 0.73 was significantly different from unity. Apparently the necessary conditions for simple competitive inhibition were not met. To assess the significance of this finding we have assayed the activity of burimamide, metiamide and cimetidine on the isolated, lumen-perfused whole mouse stomach preparation (Angus & Black, 1978).

Each preparation was equilibrated with a single

**Table 1** pA<sub>2</sub> and n values (equivalent to the slope in the Schild plot) with 95% confidence limits for gastric acid secretion in the isolated mouse stomach. For comparison, previously reported pA<sub>2</sub> values for atria and uterus are also given (Black et al., 1972(a); 1973(b); Brimblecombe et al., 1975(c); Parsons et al., 1977(d).

Antagonist	Agonist	Gastric Secretion		Atria	Uterus
		pA₂(±95%CL)	n(±95%CL)	$pA_2$	$pA_2$
Burimamide	Histamine	4.59 (0.23)	0.98 (0.24)	5.11 <sup>(a)</sup>	5.17 <sup>(a)</sup>
Metiamide	Histamine	5.08 (0.32)	0.96 (0.22)	6.04(b)	6.12 <sup>(b)</sup>
Metiamide	Dimaprit	5.23 (0.25)	1.17 (0.23)	6.19 <sup>(d)</sup>	6.07 <sup>(d)</sup>
Cimetidine	Histamine	5.14 (0.31)	0.99 (0.21)	6.10 <sup>(c)</sup>	6.09 <sup>(c)</sup>

agonist concentration with or without previous incubation with antagonist (up to  $3 \times 10^{-3}$  M). A single assay consisted of 90 stomachs, 15 preparations on each of 6 experimental days. Three-point doseresponse curves were constructed for the control and for each of four dose-levels of antagonist. The stomachs on any one day were randomly allocated to the 15 treatments so that a complete block was done each day. The antagonist was added to the bath 20 min after setting up the preparation and a further 40 min later the agonist was added. Responses were taken as log (peak [H+] nmol/min) to balance the effect of experimental error at the different response levels. The data were analyzed by fitting linear equations to all 90 observations generally following the iterative technique of Waud (1975) with the use of a PDP-11 computer and GLIM statistical package.

Table 1 shows the pA2 values and n values (equivalent to the slope in the Schild plot) together with 95% confidence limits. For each study, the n value was not significantly different from unity suggesting that simple competitive inhibition was present. The pA<sub>2</sub> values were significantly lower than the values reported previously for atria and uterus. (Black, Duncan, Durant, Ganellin & Parsons, 1972; Black, Duncan, Emmett, Ganellin, Hesselbo, Parsons & Wyllie, 1973; Brimblecombe, Duncan, Durant, Emmett, Ganellin & Parsons, 1975). Approximately a 10-fold difference in potency was observed for metiamide and cimetidine and four-fold for burimamide. The pA<sub>2</sub> value for metiamide against dimaprit, the selective H<sub>2</sub>-receptor agonist, (Parsons, Owen, Ganellin & Durant, 1977) was not significantly different from that found using histamine. Bunce & Parsons (1976) suggested that the low slope in their Schild plot for metiamide might be due to a loss of antagonist from the bath diffusing through the tissue into the lumen and out with the perfusate. We have detected a small amount of [C14]-metiamide in the lumen perfusate (collected over 40 min) but this amounted to less than 0.1% of the bath [C14]metiamide content which is probably not sufficient to distort the assay.

Our findings show that the  $pA_2$  values for the three  $H_2$ -antagonists were significantly lower than the estimates from atria and uterus. Perhaps there is an

uptake mechanism for histamine which all the antagonists also block or there is a different sub-set of receptors. However, Sjostrand, Ryberg & Olbe (1977) have reported pA<sub>2</sub> values for metiamide and cimetidine of 4.82 and 5.82 respectively using isolated sheets of guinea pig mucosa and so it would seem prudent to reserve judgement about the significance of our results until the measurements have been repeated using different techniques.

J.A.A. is a holder of a National Health and Medical Research Council of Australia, C.J. Martin Fellowship. We thank Smith, Kline and French Laboratories for gifts of burimamide, metiamide and dimaprit.

## References

ANGUS, J.A. & BLACK, J.W. (1978). Production of acid secretion in the isolated mouse stomach by electrical field stimulation. *Br. J. Pharmac.*, (this issue).

BLACK, J.W., DUNCAN, W.A.M., DURANT, C.J., GANELLIN, C.R. & PARSONS, M.E. (1972). Definition and antagonism of histamine H<sub>2</sub>-receptors. *Nature*, *Lond.*, 236, 385–390.

BLACK, J.W., DUNCAN, W.A.M., EMMETT, J.C., GANELLIN, C.R., HESSELBO, T., PARSONS, M.E., & WYLLIE, J.H. (1973). Metiamide—an orally active histamine H<sub>2</sub>-receptor antagonist. *Agents and Actions*, 3, 133–137.

BRIMBLECOMBE, R.W., DUNCAN, W.A.M., DURANT, G.J., EMMETT, J.C. GANELLIN, C.R. & PARSONS, M.E. (1975). Cimetidine – a non-thiourea H<sub>2</sub>-receptor antagonist. *J. Int. Med. Res.*, **3**, 86–92.

BUNCE, K.T. & PARSONS, M.E. (1976). A quantitative study of metiamide, a histamine H<sub>2</sub>-antagonist, on the isolated whole rat stomach. *J. Physiol. (Lond.)*, **258**, 453–465.

PARSON, M.E., OWEN, D.A.A., GANELLIN, C.R. & DURANT, G.J. (1977). Dimaprit – [S-[-3-(N<sub>1</sub>N-dimethylamino)propyl] isothiourea] – a highly specific histamine H<sub>2</sub>-receptor agonist. Part 1. Pharmacology. Agents and Actions, 7, 31–37.

SJOSTRAND, S.E., RYBERG, B. & OLBE, L. (1977). Analysis of the actions of cimetidine and metiamide on gastric acid secretion in the isolated guinea-pig gastric mucosa. *Naunyn-Schmiedeberg's Arch. Pharmacol.*, 296, 139-142.

WAUD, D.R. (1975). Analysis of dose-response curves. In: Methods in Pharmacology, Vol. 3, ed. Daniel, E.E. & Paton, M. pp. 471-505. New York: Plenum Press.